Literature DB >> 24405164

A systematic review of the safety of probiotics.

Tina Didari1, Sara Solki, Shilan Mozaffari, Shekoufeh Nikfar, Mohammad Abdollahi.   

Abstract

INTRODUCTION: There is growing evidence on the use of probiotics in various diseases, especially in gastrointestinal (GI) diseases. Although probiotics have been found helpful in many illnesses, they do not always seem to be safe. Through interference with commensal microflora, they can result in opportunistic performances in the host due to bacterimia and fungemia. Since considerable numbers of consumers use probiotic products worldwide, assurance of safety of these products is necessary. AREAS COVERED: This review evaluates all the existing information about the safety of probiotics in humans and animal models up to May 2013. In all eligible published studies in which adverse effects and tolerability of probiotics were investigated and reported, no language limitations were applied. The main key search terms were 'probiotics,' 'safety,' 'side effects,' 'clinical trial' and 'adverse effects.' The vast majority of trials investigated Bifidobacterium (B) and Lactobacillus (L) species. EXPERT OPINION: The main observed adverse effects of probiotics were sepsis, fungemia and GI ischemia. Generally, critically ill patients in intensive care units, critically sick infants, postoperative and hospitalized patients and patients with immune-compromised complexity were the most at-risk populations. While the overwhelming existing evidence suggests that probiotics are safe, complete consideration of risk-benefit ratio before prescribing is recommended.

Entities:  

Mesh:

Year:  2014        PMID: 24405164     DOI: 10.1517/14740338.2014.872627

Source DB:  PubMed          Journal:  Expert Opin Drug Saf        ISSN: 1474-0338            Impact factor:   4.250


  71 in total

1.  In vitro investigation of Debaryomyces hansenii strains for potential probiotic properties.

Authors:  Honeylet Sabas Ochangco; Amparo Gamero; Ida M Smith; Jeffrey E Christensen; Lene Jespersen; Nils Arneborg
Journal:  World J Microbiol Biotechnol       Date:  2016-07-18       Impact factor: 3.312

2.  Beneficial effect of butyrate, Lactobacillus casei and L-carnitine combination in preference to each in experimental colitis.

Authors:  Mahsa Moeinian; Seyedeh Farnaz Ghasemi-Niri; Shilan Mozaffari; Amir Hossein Abdolghaffari; Maryam Baeeri; Mona Navaea-Nigjeh; Mohammad Abdollahi
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

Review 3.  Contemporary meta-analysis of short-term probiotic consumption on gastrointestinal transit.

Authors:  Larry E Miller; Angela K Zimmermann; Arthur C Ouwehand
Journal:  World J Gastroenterol       Date:  2016-06-07       Impact factor: 5.742

4.  Probiotic-associated aspiration pneumonia due to Lactobacillus rhamnosus.

Authors:  Christopher D Doern; Sean T Nguyen; Folashade Afolabi; Carey-Ann D Burnham
Journal:  J Clin Microbiol       Date:  2014-06-04       Impact factor: 5.948

Review 5.  Effectiveness of probiotics in irritable bowel syndrome: Updated systematic review with meta-analysis.

Authors:  Tina Didari; Shilan Mozaffari; Shekoufeh Nikfar; Mohammad Abdollahi
Journal:  World J Gastroenterol       Date:  2015-03-14       Impact factor: 5.742

Review 6.  Quantitative Risk-Benefit Analysis of Probiotic Use for Irritable Bowel Syndrome and Inflammatory Bowel Disease.

Authors:  William E Bennett
Journal:  Drug Saf       Date:  2016-04       Impact factor: 5.606

Review 7.  Nutraceuticals as modulators of gut microbiota: Role in therapy.

Authors:  Eamonn M M Quigley
Journal:  Br J Pharmacol       Date:  2020-01-03       Impact factor: 8.739

Review 8.  Systematic review and meta-analysis: the effects of fermented milk with Bifidobacterium lactis CNCM I-2494 and lactic acid bacteria on gastrointestinal discomfort in the general adult population.

Authors:  Jacqui Eales; Peter Gibson; Peter Whorwell; John Kellow; Ann Yellowlees; Richard H J Perry; Mary Edwards; Sarah King; Hannah Wood; Julie Glanville
Journal:  Therap Adv Gastroenterol       Date:  2016-10-10       Impact factor: 4.409

Review 9.  Probiotics, fibre and herbal medicinal products for functional and inflammatory bowel disorders.

Authors:  Diego Currò; Gianluca Ianiro; Silvia Pecere; Stefano Bibbò; Giovanni Cammarota
Journal:  Br J Pharmacol       Date:  2016-10-25       Impact factor: 8.739

10.  In vitro screening and in vivo colonization pilot model of Lactobacillus plantarum LP5 and Campylobacter coli DSPV 458 in mice.

Authors:  M J Ruiz; M V Zbrun; M L Signorini; J A Zimmermann; L P Soto; M R Rosmini; L S Frizzo
Journal:  Arch Microbiol       Date:  2021-06-01       Impact factor: 2.552

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.